Article Text
Letter
Safety and efficacy of TNFα blockade in relapsing vasculitis
Statistics from Altmetric.com
Blockade of tumour necrosis factor alpha (TNFα) using infliximab, a chimeric monoclonal antibody against TNFα, is an effective treatment in rheumatoid arthritis and Crohn's disease.1, 2 Sifikakis reported success using infliximab in sight threatening Behçet's disease.3 A preliminary study has also reported clinical improvements in the primary systemic vasculitis, Wegener's granulomatosis, with the soluble TNFα receptor etanercept.4 The benefit of lenercept, a soluble p55 TNFα receptor fusion protein, on digital vasculitis in rheumatoid arthritis has also …